The filaggrin gene (FLG) is essential for skin differentiation and epidermal barrier formation with links to skin diseases, however it has a highly repetitive nucleotide sequence containing very limited stretches of unique nucleotides for precise mapping to reference genomes.
ABSTRACT
The filaggrin gene (FLG) is essential for skin differentiation and epidermal barrier formation with links to skin diseases, however it has a highly repetitive nucleotide sequence containing very limited stretches of unique nucleotides for precise mapping to reference genomes.
Sequencing strategies using polymerase chain reaction (PCR) and conventional Sanger sequencing have been successful for complete FLG coding DNA sequence amplification to identify pathogenic mutations but this time-consuming, labour intensive method has restricted utility. Next-generation sequencing (NGS) offers obvious benefits to accelerate FLG analysis but standard re-sequencing techniques such as oligoprobe-based exome or customized targeted-capture can be expensive, especially for a single target gene of interest.
We therefore designed a protocol to improve FLG sequencing throughput using a set of FLG-specific PCR primer assays compatible with microfluidic amplification, multiplexing and current NGS protocols. Using DNA reference samples with known FLG genotypes for benchmarking, this protocol is shown to be concordant for variant detection across different sequencing methodologies. We applied this methodology to analyze cohorts from ethnicities previously not studied for FLG variants and demonstrate usefulness for discovery projects.
This comprehensive coverage sequencing protocol is labour-efficient and offers an affordable solution to scale up FLG sequencing for larger cohorts. Robust and rapid FLG sequencing can improve patient stratification for research projects and provide a framework for gene specific diagnosis in the future.
INTRODUCTION
The filaggrin gene (FLG) encodes profilaggrin, a major epidermal structural protein with multifunctional roles essential for effective skin barrier formation McAleer and Irvine 2013) . Loss-of-function (LoF) variants in FLG have been identified as the causative genetic defect in the dry skin condition ichthyosis vulgaris (IV; OMIM 146700) and represent the most significant genetic variants associated with risk of atopic dermatitis (AD) (Palmer et al. 2006; Smith et al. 2006; van den Oord and Sheikh 2009) . IV is one of the most common inherited skin diseases with surveys reporting a population prevalence of up to 1 in 250, with AD often present as a secondary trait but with lower penetrance (Wells and Kerr 1966; Smith et al. 2006) . AD is a prevalent inflammatory skin barrier deficiency affecting up to 25% of children in developed countries (Tay et al. 2002; Sandilands et al. 2006; Odhiambo et al. 2009 ). The incidence of FLG LoF alleles in AD patients varies considerably around the world with Asian ethnic populations suggesting a 20 -30% mutation burden whilst in northern Europe the incidence can be up to 50% (Sandilands et al. 2007; Brown et al. 2008a; Chen et al. 2011; Kono et al. 2014 ). The reasons underlying geographical variations in combined mutation frequencies are unclear but their maintenance within the gene pool is consistent with a heterozygote advantage (Irvine and McLean 2006; Thyssen et al. 2014; Eaaswarkhanth et al. 2016) , although the basis for this is still under debate. Recent research has confirmed that FLG LoF variants are associated with early-onset, more severe and persistent AD, highlighting a primary skin barrier dysfunction in this disorder (Brown et al. 2008b; Fallon et al. 2009 ).
Distinct sets of LoF variants are present in different ethnicities. In the northern European population, two predominant sequence variants make up 80% of the mutation burden (Sandilands et al. 2007) . In contrast, in east Asian ethnicities (cohorts from Japan, Taiwan, Singaporean Chinese, Korea and China), more diversity of FLG LoF variants are found with fewer predominating variants, resulting in a wider mutation spectrum compared to 4 Caucasian populations (Chen et al. 2011; Irvine et al. 2011 ). In addition, many rare familyspecific and country-specific LoF variants have been reported, adding to the global complexity of FLG pathogenic mutation identification. Compilation of published data has identified 85 FLG LoF disease-associated variants to date ( Supplemental Table 1 ) and 252 FLG LoF variants identified in multiple ethnic populations (without disease information) from exome sequencing data deposited in the Exome Aggregation Consortium (ExAC;
Supplemental Table 2 ) (Thyssen et al. 2014; Lek et al. 2016) .
The filaggrin gene is a member of the S100 fused-type gene family, a group of genes with a conserved exon structure and likely shared functions in epithelial biology (Gan et al. 1990; Henry et al. 2012; Strasser et al. 2014) . FLG transcription is initiated in exon 2 with the majority of the profilaggrin polyprotein produced from the extremely long (>12Kb) and highly repetitive exon 3. The genetic architecture of exon 3 consists of 10, 11 or 12 tandemly arranged filaggrin repeat units, each approximately 972 nucleotide base pairs (bp) long and joined by a 21 bp linker region (Gan et al. 1990 ). Intragenic copy number variation (CNV) of filaggrin repeats increases the gene structure complexity, with each repetitive unit almost identical in sequence (Sandilands et al. 2007; Sasaki et al. 2008; . The presence of these numerous highly repetitive stretches of nucleotide sequences makes primer design challenging, and restricts primer site availability to a small number of unique bases present in the filaggrin repeat units and their linker regions (Sandilands et al. 2007; Sandilands et al. 2009 ). Taken together, the genetic architecture of FLG makes routine analysis by PCR and Sanger sequencing extremely laborious.
To study genetics of AD properly in any given population, appropriate stratification to determine risk predictions is essential, whether for research studies or clinical trials.
Therefore a fast, robust, comprehensive and affordable method for FLG coding DNA sequence (CDS) analysis is required. To date, most FLG studies have taken the approach of targeted screening for the predominant common LoF variants to report allele frequencies 5 after full sequencing of an initial small batch of test patient samples. This strategy runs the risk of under-reporting in populations where FLG LoF variantss are highly diverse, due to discovery sampling effects (Clark et al. 2005) . Whilst full Sanger sequencing of the FLG CDS is not feasible in all laboratories, it is still necessary in order to provide comprehensive study results (Sandilands et al. 2007) . Target capture techniques such as exome sequencing captures FLG LoF variants but is currently expensive if the aim is to study a single gene. Also, due to the occurrence of rare and de novo family specific FLG LoF variants, the over reliance on publically available aggregated summary sequencing data will not inform sufficiently for LoF targeted screening of FLG (Margolis et al. 2014; Lek et al. 2016; Ruderfer et al. 2016) .
In this paper we describe a simple, robust and cost-effective PCR-based method for analyzing the entire CDS of FLG including the well known intragenic CNVs. This protocol uses microfluidics technology to reduce the amount of DNA starting material needed, increases sample throughput and reduces the required operator time for comprehensive FLG genotyping. Coupling this sample preparation protocol with relatively long NGS reads and a streamlined bioinformatics pipeline for analysis, we present a scalable solution for efficient cohort analysis. This protocol also removes the ascertainment bias introduced by only screening for the most common population-specific FLG LoF variants (Clark et al. 2005) .
The potential usefulness of a robust protocol to identify FLG sequence variants extends beyond the research environment and could aid clinical diagnosis and patient treatments as more pharmacogenetic therapies for AD are developed Margolis et al. 2013) . This approach to sequencing FLG could also be applied to other large complex genes that are difficult to analyze, such as the additional members of the S-100 family.
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RESULTS
Establishing a validated protocol for FLG CDS amplicon sequencing
We designed and optimized a set of 48 FLG-specific primer assays (containing sequencing adapters) to span the entire FLG CDS and generate overlapping amplicons suitable for downstream processing and paired-end sequencing with Illumina MiSeq NGS (MiSeq Reagent Kit v2, 2 x 250 bp read mode; Supplemental Table 3 ). Each of the 48 primer assays was designed with an amplicon size between 400 and 500 bp. Analyzing conventional PCR reactions confirmed accurate amplicon sizing of a single major PCR band with minimal generation of non-specific products ( Figure 1A ). Overlapping primer pair assays were designed to provide redundancy in sequencing reads across primer binding sites. In particular, the regions between repeat 7 and repeat 8 or 8 1 were heavily overlapped with amplicon design to improve coverage ( Figure 1B ). This also enabled confirmation that single nucleotide variations (SNV) were not present in primer binding sites, as this could result in the loss of PCR amplicons.
The Access Array 48.48 integrated fluidic circuit (IFC) chip (Fluidigm, US), hereafter referred to as the Access Array IFC, allows for parallel amplification of 48 amplicons for 48 different DNA samples, simultaneously generating 2304 PCR reactions with nanolitre volumes suitable for downstream massively parallel sequencing projects (Lange et al. 2014) . 96 different DNA samples were analyzed in a pilot experiment using two Access Array IFC chips. Amplicons were tagged with sample-specific barcodes during the PCR process to facilitate downstream multiplexed MiSeq NGS (Illumina). Amplicon pools from each Access Array IFC were visualized for correct amplification product size with Bioanalyser (Agilent) prior to bead purification ( Figure 1C ). Out of the 96 samples run on the two Access Array IFC, four samples did not produce libraries and were omitted from further analysis.
Subsequently the PCR products from two Access Array IFC chips were combined to produce a single amplicon pool containing the 92 barcoded DNA amplicon libraries that were 7 successfully amplified. These 92 were again sized with Bioanalyser ( Figure 1D ), before sequencing on the Illumina MiSeq using 2 x 250 bp mode (see Methods). Importantly, primer dimer contaminants that could potentially interfere with downstream sequencing were removed from the final amplicon pool using bead purification ( Figure 1D ). Sequencing of this pool on the Illumina MiSeq 2 x 250 bp mode resulted in high average sequencing depth per base that corresponds to the number of multiplexed DNA samples.
Sequence reads were mapped to the previously reported 12-repeat FLG reference sequence (Sandilands et al. 2007 ) using the BWA-MEM algorithm (Li 2013) . This reference sequence contains the variably present additional intragenic CNV allelic variants of repeat 8 and repeat 10 but is not currently documented in the NCBI RefSeq database. The mapped reads were processed with the GATK suite of tools (McKenna et al. 2010) . Quality control of the reads and variants was ensured by the internal functions of GATK (see Methods). By default our pipeline returns mapping files (BAM format) and variant call files (VCF format).
Functional annotation of variants was added with the SnpEff tool (Cingolani et al. 2012) .
Visual inspection of identified null-mutations was performed using the Integrated Genome Viewer (Broad Institute; Figure 1E ) (Robinson et al. 2011) . In an optional pipeline step, the coordinates of identified variants can also be converted to the FLG gene 10-repeat reference sequence that is found in current genome annotations (RefSeq GRCh37 or GRCh38). One of the genomic features of FLG that we aimed to assess in our samples was the presence or absence of intragenic CNV of repeats 8 and 10 (Figure 2A) , as this is an important risk factor for AD . Complete 12-repeat FLG CDS coverage was achieved with 48 primer assays that encompassed the known intragenic CNV allelic variants. Primer assays 34, 35 and 41 ( Figure 1B ; Supplemental Table 3 ) amplify multiple segments of FLG repeats 8 and 10 and their CNVs. Amplicons were then mapped to the CNV repeat regions using unique nucleotide bases that differentiate between the FLG
repeats.
For identification of repeat 10 CNV, we observed that absence of duplication (i.e.
having the canonical repeats 9, 10 and 11 in sequence) would coincide with a complete drop in coverage in the region 22500-23000 of the 12 repeat reference CDS, corresponding to the position of 10 2 ( Figure 2B) . Likewise, the presence of repeat 10 duplication (i.e. repeats 9, 10 1 , 10 2 , 11) would manifest as the presence of sequencing reads covering this same region of the FLG reference CDS ( Figure 2B ). DNA sample profiles for repeat 10 CNV were confirmed using PCR and gel electrophoresis ( Figure 2C) . We were therefore able to calculate four ratios from our NGS data based on the number of mapped reads in the 10 2 region normalising to: 1) total number of mappings, 2) total number of reads with at least one mapping, 3) number of reads in FLG coordinates for 10 1 (15480-15950) and 4) 10 2 (23500-24000), of the FLG 12-repeat reference sequence where coverage is stable over approximately 500 bp. The distribution of these ratios shows three distinct peaks:
homozygous reference (near zero on the X axis), heterozygous and homozygous duplicated ( Figure 2D ). The latter two peaks can sometimes merge at the tails depending on the quality of the samples. If this is observed, samples in this overlapping region are marked as ambiguous. When three of these ratios are in agreement the repeat is called automatically (90 out of 92 samples). If not, visual inspection of the data with IGV is used to assess the repeat status (2 out of 92). These peaks can be slightly shifted for separate batches of samples but are always distinctly observable in the batches processed thus far.
Filaggrin repeat 8 1 and 8 2 have near identical sequence homology resulting in NGS reads potentially mapping to either genomic region. When calculating intragenic variation for filaggrin repeat 8 we studied coverage using the 4 ratios described above but did not rely on coverage alone to distinguish CNV identity ( Figure 2E ). In Singapore Chinese DNA samples that we analysed we could differentiate between repeat 8 1 and 8 2 using a T to G intragenic allelic variant between CNV repeats ( Figure 2F ). However, this particular variant was not informative for CNV identification in Caucasian samples we analysed (data not shown).
Based on the allele frequency of the SNV together with coverage data we make a call regarding the presence of repeat 8 2 . Finally, this result was correlated with a specific conventional PCR and electrophoresis to confirm the repeat 8 CNV profile in representative samples ( Figure 2G ).
The methodology described here constitutes a validated high throughput PCR-based amplification, NGS and bioinformatics analysis protocol for comprehensive analysis of the FLG CDS (Supplemental Figure 1 ). This protocol is amenable to further scaling up of sample throughput, thus providing a means for rapid turnaround of large cohorts for targeted FLG resequencing. Analysis of sequencing paired-end reads provided high quality FLG genotyping that can provide more than adequate depth for base calling in mutation analysis and also estimates of intragenic CNV. Coverage predictions were generated with read coverage ratios to generate distribution graph for multiple samples (n=92). Three clear peak clusters observed in the distribution graphs correspond to the intragenic repeat 10 CNV predictions. Peak 1 corresponds to homozygous for repeat unit 10 only, peak 2 corresponds to heterozygous repeat 10 units -allele 1 contains 10; allele 2 contains 10 1 /10 2 . Peak 3 on the distribution graph corresponds to homozygous CNV repeat 10 units 10 1 /10 2 . (E) For repeat 8 CNV, coverage predictions were generated using reads coverage ratios. Distribution plot indicating
FLG LoF variant detection across multiple sequencing methodologies
Using the 92 DNA samples that were fully analyzed for the pilot experiments, we compared two additional FLG sequencing strategies with the 2 x 250 bp protocol, described above, for coverage, sequencing depth and mutation detection. These were (1) Table 4 ) and (2) an Illumina MiSeq reagent kit v3, 2 x 300 bp mode with overlapping amplicons designed with an average of 546 bp (Supplemental Table 5 ). Comparing the 3 sequencing strategies, an additional 4 samples failed on at least one platform and were therefore removed from further analysis. The remaining 88 DNA samples were used for subsequent cross-platform comparison. 14 of the 88 DNA samples had been previously fully Sanger sequenced for FLG CDS using well established published primers (Sandilands et al. 2007; Chen et al. 2011 ) and thus their FLG LoF variant profile was known. FLG variant profile in these 14 samples across the 3 investigated protocols was similar but only the MiSeq methods detected the full complement of disease associated FLG LoF variants ( The Roche 454 GS FLX+ protocol produced longer read lengths that potentially provided more accurate read mapping and better resolution of intragenic CNV repeats.
However, although this method was able to identify the majority of FLG LoF variants 14 correctly (Table 1) , major difficulties were encountered in distinguishing true insertions and deletions from false positives due to the inherent limitation of the 454 GS FLX+ in interpreting homopolymer sequences (Balzer et al. 2011) . Additionally, sequencing depth of FLG CDS lacked uniformity, probably due to uneven amplicon size within our design.
We used the MiSeq reagent kit v3, 2 x 300 bp protocol to maximize amplicon length with Illumina sequencing that potentiated more accurate mapping for this system and larger overlap of amplicons. However, the MiSeq reagent kit v3, 2 x 300 bp mode resulted in suboptimal quality control, reporting poor base call Q scores that raised the probability of falsepositive variant calls in sequencing reads (63.6% of bases had a Q score of 30 or higher for the pilot run of 88 samples). Despite sequencing data with suboptimal Q30 scores, the erroneous variants were interspersed at low frequency throughout the gene, so that with deep sequencing per base coverage we were able to unambiguously identify all FLG LoF variants in line with the other sequencing techniques analyzed (Table 1 ). In comparison, primer assays specifically designed for Illumina MiSeq 2 x 250 bp protocol produced good overall sequencing coverage with higher quality scores (80.9% of bases with Q score >30 for pilot experiment of 92 samples), FLG LoF variants were all detected according to the known sample profiles (Table 1) IA-P003 p.S1515X p.S1515X p.S1515X p.S1515X IA-P084 p.S1302X; ND p.S1302X; p.S1515X p.S1302X; p.S1515X p.S1302X; p.S1515X Table 7 ). 85 of these IV and/or AD samples had previously been
Sanger sequenced for the entire FLG CDS in our earlier study (Chen et al. 2011 ). This
reanalysis provided a validation experiment for FLG LoF variant detection in comparison to
Sanger sequencing. In this comparison we identified one additional mutation with Access Array IFC amplification and MiSeq sequencing that was not picked up in our previous study (Supplemental Table 8 ). Complete CDS sequencing of the remaining 194 DNA samples identified 11 additional variants in the Singapore Chinese population, bringing the total number of variants identified to 32 (an increase from 22 in our previous study), with five variants not previously reported in the literature (Figure 3; Figure 4 ). Fisher's exact test on the FLG LoF variants using ExAC (version 0.3.1) exome data as population controls showed that 14 LoF variants reached individual significance of p<0.05 (Supplemental Table 9 ). Table 7 and Supplemental Table 10 .
Chinese Malay Indian
Subjects demographics
Subjects ( Table 10 ). We identified FLG LoF variants in nine of the Indian samples (Table 3 ) and nine Malay samples (Table 3) , therefore predicted to have disease relevance, as reported for all FLG LoF variants in other ethnic groups. All predicted disease-associated sequence variants were analysed for predicted function using MutationTaster2 (Schwarz et al. 2014 ) and validated by Sanger sequencing (Sandilands et al. 2007 ).
Applying the Access Array IFC FLG sequencing methodology to cohorts of divergent ethnic ancestry, we have analyzed a total of 334 Singaporean IV and/or AD samples.
Specifically using MiSeq 2 x 250 bp protocol we identified additional FLG LoF variants, bringing the combined mutation allele frequency for Singapore Chinese AD patients up to 32.3% (analysis of 279 AD patients). FLG LoF variants were also investigated in Indian and Malay ethnicities from Singapore with IV and/or AD, which identified additional LoF variants and confirms a variable incidence of FLG linked AD between different ethnic groups (Indians at 47.4% in 19 patients and Malays 25% in 36 patients; Figure 4) . The presence of a FLG LoF variant in patients did not significantly alter the SCORAD from those without FLG LoF variants in the cohorts studied (Table 2 ).
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DISCUSSION
The association of FLG LoF variants with skin and allergic diseases has been one of the most profound and impactful discoveries in human molecular genetics. Mutations in FLG have an impact both on causation and on risk of disease that blur the boundaries between single gene and complex traits disorders (Palmer et al. 2006; Smith et al. 2006; Irvine et al. 2011 ). Various hypotheses have been put forward about the potential evolutionary advantage of maintaining FLG LoF alleles in populations, ranging from vitamin D synthesis to trans-dermal immunisation, although no clear advantage has been confirmed (Irvine and McLean 2006; Thyssen et al. 2012; Thyssen et al. 2014; Nagao and Segre 2015; Eaaswarkhanth et al. 2016 ). Due to the size and complexity of the FLG gene, together with the cost and analysis time, the complete FLG CDS is rarely comprehensively sequenced and therefore the full spectrum of FLG variants is not completely realized in many patient cohorts. A non-NGS 'FLG-shotgun' sequencing method has previously been reported but not widely adopted possibly due to bacterial cloning steps (Sasaki et al. 2008) . The capacity to efficiently study FLG is important because of its role in the pathogenesis of common skin disorders such as IV (1 in 250) and AD (1 in 5) that could be targeted with early therapies, such as emollients, to prevent disease progression. In this study we describe a protocol for amplification and sequencing of the entire FLG CDS for multiple patients with a semiautomated and affordable methodology that costs approximately 10 times less than exome target capture. We also show that this protocol is robust, reliable and has potential for scalable sample preparation for small and large research projects or clinical studies.
NGS has changed the landscape of mutation discovery with whole exome sequencing (Ng et al. 2009 ) and target capture of candidate genes or genetically linked regions becoming a common laboratory practice for research and diagnostic outcomes (Berg et al. 2011; Goudie et al. 2011; Artuso et al. 2012; Scott et al. 2012 ). In the work presented here, we used the power of NGS but circumvented the challenges of only 23 resequencing one target gene by incorporating a multiplexed PCR step that provides an affordable way to look at FLG CDS in multiple samples in parallel. The relatively small capture size of 15 Kb for targeted re-sequencing experiments provided the opportunity to design an overlapping PCR strategy for FLG with inbuilt redundancy to capture the entire CDS. This, coupled with use of the Access Array IFC, facilitates high-throughput PCR amplification of multiplexed samples. This approach requires minimal amounts of high quality starting DNA for the assay (50 ng), plus reduced PCR reagents per reaction using the microfluidics set up (0.16 µl), and significantly reduced manpower is required in comparison to other strategies, making this an extremely cost-efficient protocol to run.
Flexibility in the number of pooled DNA sample amplicon libraries prepared for a single
MiSeq sequencing lane is also an advantage and can be tailored to experimental size and sequencing depth required -the upper limit currently determined by the availability of unique sample barcodes. We have routinely multiplexed 96 samples, but have also successfully The benefits of our assay over conventional PCR strategies are clear, but there are potential problems and pitfalls to be considered. Sample batching can result in time delays prior to running the assay, although it is possible to run less than 96 samples albeit at increasing cost per sample. Experimentally there is always the possibility of amplification problems using primer assays -for example, the presence of an SNV in a primer-binding site of one allele could result in primer-binding failure, or reduced efficiency in generation of that allele's amplicon during PCR amplification (allele dropout). Detection of allele dropout remains challenging and although we have not detected this in our sequencing so far, PCR amplification methods can be subject to loss of coverage of one allele. To reduce the chances of this happening, we designed all our primer assays with overlapping amplicon 24 fragments and can check for SNVs in the primer sites if low sequencing read coverage is detected. Other potential pitfalls are mapping errors on this highly repetitive gene and reference bias. We retained standard calling thresholds for GATK for detection of mutations that allow for considerable deviation from the theoretical allele frequencies of 0%, 50% and 100%. This potentially leads to an increased number of false-positives, but conversely we were able to detect a heterozygous variant (c.9040_9058dup19) at 11% mutant to 89% wild type ratio. We therefore validated all deleterious variants with conventional PCR and Sanger sequencing as an additional confirmation step to ensure accurate reporting.
There are also practical cost considerations in the initial set-up. The initial outlay for this assay requires high quality primer assays and specialist equipment for NGS, and access to a Fluidigm thermocycler is essential for running the Access Array 48.48 IFC. We have designed this assay to run on the Illumina MiSeq for entry-level costing and it is closely related to the MiSeqDX that is increasingly found in clinical units and has been approved by the FDA for clinical diagnostics for certain applications. The MiSeq outputs fewer reads than 
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In conclusion, we present a fast and robust method to approach high-throughput sequencing of the long and highly repetitive FLG coding sequence. This validated protocol enables rapid identification of gene mutations in patients to facilitate research studies and possibly genetic diagnostics in the future. Illumina sequencing platforms are widely used for clinical diagnostics, and therefore we envisage this as a step toward developing a clinical diagnostic strategy for FLG sequencing. Making FLG genotyping accessible to researchers and clinicians studying patients from any ethnicity with an unbiased approach is vital to progress a precision medicine approach to AD and indeed any other difficult to sequence genes. The identification of FLG risk genotypes will allow for a more informed approach towards treating and hopefully preventing the development of AD. The heterogeneous nature of AD and the genetic basis of inter-individual differences in drug responses will make risk genotypes particularly relevant for the development of personalised pharmacogenetic therapies and the use of skin barrier maintenance treatments.
METHODS
Sample collection
A total of 367 samples were used in this study ( Supplemental Table 11 
Bioinformatics analysis of 454 and MiSeq
Raw sequence files were processed using a custom pipeline implemented in Pipeline Pilot (www.accelrys.com). Input reads were mapped to a FLG reference sequence containing 12 repeats that included the intragenic CNVs, introns, 5' and 3' UTRs that is not currently available as an NCBI RefSeq (Sandilands et al. 2007) . We used BWA-MEM (version 0.7.10-r789) with the following parameters: gap opening penalty = 8, gap extension penalty = 2, mismatch penalty = 4, match score = 1 and minimum score threshold = 100.
The mapped reads are stored as indexed BAM files which are then processed with GATK toolkit (version v3.4-46-gbc02625, Java version 1.7.0_75). HaplotypeCaller module was used to calculate SNVs and indels for each sample separately. Settings for HaplotypeCaller were as follows: minimum variant quality = 10, minimum pass quality = 50, maximum deletion length =12 and coverage was downsampled to 2500 in high-coverage regions. The individual gVCF files for each sample can then be collectively processed with the GenotypeGVCFs module to produce a joint VCF report for multiple samples (same quality cut-offs). This approach is flexible and scalable and increases the sensitivity of SNV detection (McKenna et al. 2010) .
The pipeline returns a VCF report. The user can optionally reverse complement and convert the variants to GRCh37 or GRCh38 coordinates. Variants identified in the 8 2 or 10 2 repeat were not mapped to these reference coordinates. The VCF files can be annotated with the SnpEff tool (version 4.2) to annotate the SNVs and assess their impact. SnpEff was run with default options with the exception of lof.deleteProteinCodingBases which was set to 0.50.
PCR and Sanger-sequencing of FLG
We comprehensively amplified the entire FLG open reading frame as previously described (Sandilands et al. 2007; Chen et al. 2011) . PCR products were Sanger sequenced using the chain-terminator fluorescently-labelled dideoxyribonucleotidetriphosphate method (BigDye V3, ABI) and subjected to capillary electrophoresis on a ABI Prism ® 377 DNA Sequencer in order to determine the sequence of each PCR product Chen et al., 2011) . Electropherograms were analyzed using the Lasergene suite of sequencing analysis programs (DNASTAR). Sanger sequencing was also used to validate all FLG LoF variants identified by NGS using previous published primers (Sandilands et al. 2007; Chen et al. 2011) .
Repeat 8 and repeat 10 regions in FLG exon 3 were amplified by PCR reactions (20 μL) using the Expand High Fidelity PLUS PCR System (Roche) with 100 ng of genomic DNA, 1.5 U of enzyme, 1× Buffer 2, dNTPs (250 µM), 0.5 µM each of the forward and reverse primers and 4% v/v DMSO. PCR products were separated on a 0.9% w/v agarose gel and CNVs distinguished by their different sized products. The primers used for repeat 8 specific PCR were 5'-CCCAGGACAAGCAGGAACT-3' and 5'-GCTTCATGGTGATGCGACCA-3' (Sandilands et al. 2007 ). The primers used for repeat 10 specific PCR were 5'-GGGCCCAGGACAAGCAGGAAC-3' (in-house designed) and 5'-CTGCACTACCATAGCTGCC-3' (Sandilands et al. 2007 ). 
Statistical analysis of FLG
